Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matias Rodrigo Chacon"'
Autor:
Natalia Soledad Tissera, Berenice Freile, Romina Luca, Ivana Inés Pedraza, Federico Esteso, Diego Hernán Enrico, Federico Waisberg, Mariana Galli, Carolina Chacon, Fernando Sanchez Loria, Eduardo Huertas, Matias Rodrigo Chacon, Juan Manuel O'Connor
Publikováno v:
Journal of Clinical Oncology. 41:146-146
146 Background: Short-course radiotherapy (SCRT) is an option in the neoadjuvant setting of resectable stage II-III rectal cancer, as well as in stage IV disease for local control without delay to initiate systemic treatment. Short-course radiotherap
Autor:
Laura Sabina Lapuchesky, Marcos Bortz, Federico Waisberg, Diego Hernán Enrico, Luisina Ines Bruno, Cristian Alexis Ostinelli, Sergio Gabriel Rivero, Andres Rodriguez, Martin Zarba, Martin Loza, Verónica Yamila Fabiano, Mora Amat, Maria Teresa Pombo, Maria Laura Noro, Federico Andrés Coló, Reinaldo D. Chacon, Matias Rodrigo Chacon, Jorge Carlos Nadal, Adrian Nervo, Maria Victoria Costanzo
Publikováno v:
Journal of Clinical Oncology. 40:1056-1056
1056 Background: HER2-low expression, defined as HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization assay (FISH), accounts for 50% of breast cancers. There is limited and conflicting evidence regarding the efficacy
Autor:
Matias Rodrigo Chacon, Hernan J. Cutuli, Sergio Bracarda, Marco Maruzzo, Maria Teresa Bourlon, Carmel Jacobs, Begoña Pérez-Valderrama, Ignacio Magri, Martin Richardet, Piotr Centkowski, Simon Yuen Fai Fu, Pablo Gurman, Srivani Konduri, Zhuoxin Yu, Heather Vezina, Saby George, Laurence Albiges
Publikováno v:
Journal of Clinical Oncology. 40:TPS4621-TPS4621
TPS4621 Background: Nivolumab (NIVO), a programmed death-1 immune checkpoint inhibitor, has demonstrated clinical efficacy across patients with different tumor types, including clear cell renal cell carcinoma (ccRCC), when administered via IV infusio